CARRARO, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 370
EU - Europa 251
AS - Asia 74
AF - Africa 1
Totale 696
Nazione #
US - Stati Uniti d'America 368
RU - Federazione Russa 137
IT - Italia 34
IE - Irlanda 30
SE - Svezia 29
SG - Singapore 21
CN - Cina 19
HK - Hong Kong 13
DE - Germania 12
IN - India 9
JO - Giordania 7
ES - Italia 3
CA - Canada 2
GB - Regno Unito 2
ID - Indonesia 2
KR - Corea 2
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
FI - Finlandia 1
FR - Francia 1
JP - Giappone 1
NL - Olanda 1
Totale 696
Città #
Santa Clara 125
Chandler 43
Dublin 30
Moscow 24
Fairfield 21
Ashburn 17
Singapore 16
Houston 15
Seattle 13
Altamura 12
Cambridge 12
Lawrence 12
Woodbridge 12
Wilmington 11
Bremen 7
Mumbai 7
Princeton 7
Shanghai 7
Buffalo 6
Hong Kong 6
Medford 6
Florence 4
Ann Arbor 3
Beijing 3
Boston 3
Omaha 3
Yubileyny 3
Boardman 2
Dearborn 2
Falls Church 2
Jakarta 2
Los Angeles 2
Naples 2
Norwalk 2
Pune 2
San Diego 2
Suwon 2
Toronto 2
Turin 2
Abidjan 1
Andover 1
Bolzano 1
Brentford 1
Böblingen 1
Frankfurt am Main 1
Helsinki 1
Kilburn 1
Kumamoto 1
Kunming 1
Madrid 1
Pinerolo 1
Redwood City 1
Trieste 1
Wuhan 1
Totale 467
Nome #
The implication of BDNF Val66Met polymorphism in progression from subjective cognitive decline to mild cognitive impairment and Alzheimer's disease: a 9-year follow-up study 142
Assessing the effectiveness of subjective cognitive decline plus criteria in predicting the progression to Alzheimer’s disease: an 11-year follow-up study 116
Influence of apoe genotype and clock t3111c interaction with cardiovascular risk factors on the progression to alzheimer’s disease in subjective cognitive decline and mild cognitive impairment patients 99
Cerebrospinal fluid biomarkers for dementia: A case of post-lumbar puncture epidural hematoma 94
Per2 C111G polymorphism influences cognition in Subjective Cognitive Decline and Mild Cognitive Impairment. A 10-year follow-up study 93
Linguistic profiles, brain metabolic patterns and rates of amyloid-β biomarker positivity in patients with mixed primary progressive aphasia 91
Long-term efficacy and safety of Alemtuzumab in patients with RRMS: 12-year follow-up of the CAMMS223 study 72
Totale 707
Categoria #
all - tutte 2.414
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.414


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202028 0 0 0 0 0 0 6 4 5 6 4 3
2020/202148 6 1 2 9 3 0 0 7 7 6 4 3
2021/202247 2 1 6 2 0 3 0 4 1 2 9 17
2022/2023172 18 38 12 11 9 30 20 7 24 0 2 1
2023/202485 3 8 8 4 3 9 10 18 5 11 5 1
2024/2025309 17 38 22 79 97 56 0 0 0 0 0 0
Totale 707